Your browser doesn't support javascript.
loading
Chikungunya Arthritis Treatment with Methotrexate and Dexamethasone: A Randomized, Double-blind, Placebo-controlled Trial.
Amaral, José Kennedy; Lucena, Gabriela; Schoen, Robert Taylor.
Afiliação
  • Amaral JK; Department of Rheumatology, Institute of Diagnostic Medicine of Cariri, Juazeiro do Norte, Ceará, Brazil.
  • Lucena G; Regional University of Cariri, Crato, Ceará, Brazil.
  • Schoen RT; Section of Rheumatology, Yale University School of Medicine, New Haven, Connecticut, USA.
Curr Rheumatol Rev ; 20(3): 337-346, 2024.
Article em En | MEDLINE | ID: mdl-38173199
ABSTRACT

BACKGROUND:

Chikungunya fever is a reemerging epidemic disease caused by a single-stranded RNA alphavirus transmitted throughout by Aedes mosquitoes. Chikungunya virus infection is a biphasic disease in which 72% to 95% of affected individuals manifest acute chikungunya fever. Following the acute phase, more than 40% of affected individuals develop arthritis, often lasting more than 3 months, referred to as chronic chikungunya arthritis, which frequently mimics rheumatoid arthritis.

OBJECTIVE:

This study aimed to evaluate the efficacy and safety of treatment of chronic chikungunya arthritis with methotrexate and dexamethasone in a randomized, double-blind, placebo-controlled clinical trial.

METHODS:

The patients were reassessed for treatment response by the DAS28-ESR, tender joint count and swollen joint count, Patient Global Assessment, and for secondary measures, including the Health Assessment Questionnaire Disability Index and Pain Visual Analog Scale.

RESULTS:

Thirty-one subjects were randomized (placebo, n = 16; methotrexate, n = 15); 27 completed treatment and 4 discontinued during the 8-week blinded period. Among the participants, 96.8% were female, with mean ± SD age was 52.9 ± 13. The mean ± SD disease duration prior to treatment was 220.9 ± 51.2 days. At 8 weeks, methotrexate-treated subjects showed a greater numerical trend towards improvement, but there were no significant differences between methotrexate- dexamethasone group and dexamethasone (placebo) group.

CONCLUSION:

In this relatively small cohort, all of whom received background dexamethasone, there was a greater numerical improvement trend in prespecified outcome measures, but methotrexate in combination with dexamethasone was not superior to dexamethasone in chronic chikungunya arthritis.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Dexametasona / Metotrexato / Quimioterapia Combinada / Febre de Chikungunya Tipo de estudo: Clinical_trials Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Curr Rheumatol Rev Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Brasil País de publicação: Emirados Árabes Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Dexametasona / Metotrexato / Quimioterapia Combinada / Febre de Chikungunya Tipo de estudo: Clinical_trials Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Curr Rheumatol Rev Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Brasil País de publicação: Emirados Árabes Unidos